Patients exhibiting heightened TP53 levels experienced notably shorter overall survival (OS) and a substantially unfavorable prognosis in cancers such as BRCA, LGG, LUAD, PRAD, COAD, and SKCM (refer to Figure 3a–c and Figure 4a). The gene discussed is TP53; the disease is cancer.